share_log

HC Wainwright & Co. Reiterates Buy on Arcturus Therapeutics, Maintains $51 Price Target

Benzinga ·  Nov 15, 2023 10:37

HC Wainwright & Co. analyst Ed Arce reiterates Arcturus Therapeutics (NASDAQ:ARCT) with a Buy and maintains $51 price target.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment